

Prof. Bülent ÇETİN

Personal Information

Fax Phone: [+90 246 237 1165](tel:+902462371165)

Email: bulentcetin@sdu.edu.tr

Education Information

Post Doctorate, Suleyman Demirel University, Tıp Fakültesi, Onkoloji Bilim Dalı-Profesör, Turkey 2018 - Continues

Post Doctorate, Recep Tayyip Erdogan University, Tıp Fakültesi, Onkoloji-Doçent, Turkey 2015 - 2018

Post Doctorate, Van Eğitim Ve Araştırma Hastanesi, İç Hastalıkları, Onkoloji-Uzmanlık, Turkey 2013 - 2014

Post Doctorate of Medicine, Gazi University, Tıp Fakültesi, Onkoloji Bilim Dalı, Turkey 2009 - 2013

Expertise In Medicine, Dicle University, Tıp Fakültesi, İç Hastalıkları, Turkey 2001 - 2006

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Second Primary Tumors in Patients with Gastrointestinal Stromal Tumors: A Single-Center Experience**
Kocer M., Muallaoglu S., ÇETİN B., COŞKUN H. Ş. , KARAHAN N., GÜRDAL O.
MEDICINA-LITHUANIA, vol.57, no.5, 2021 (Journal Indexed in SCI)
- II. **Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib**
ÇETİN B., IŞIK GÖNÜL İ., GÜMÜŞAY Ö., AFŞAR B., Bilgetekin I., ÖZET A., ÜNER A.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.17, no.2, pp.408-413, 2021 (Journal Indexed in SCI)
- III. **Understanding relevant immune mechanisms in gastrointestinal oncology**
ÇETİN B., Gumusay O.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021 (Journal Indexed in SCI)
- IV. **Can you draw the picture of happiness- Treatment of a young woman with breast cancer during the COVID-19 pandemic**
ÇETİN B., RAKICI S., Gumusay O.
ASIAN JOURNAL OF PSYCHIATRY, vol.52, 2020 (Journal Indexed in SCI)
- V. **Pembrolizumab for Early Triple-Negative Breast Cancer**
ÇETİN B., Gumusay O.
NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.26, 2020 (Journal Indexed in SCI)
- VI. **Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios**
ÇETİN B., KOŞAR A.
INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.51, no.12, pp.2107-2117, 2019 (Journal Indexed in SCI)
- VII. **Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?**
ÇETİN B., Bilgetekin I., Ozet A.
CURRENT PROBLEMS IN CANCER, vol.43, no.1, pp.43-53, 2019 (Journal Indexed in SCI)

VIII. Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model

Cetin B., Yilmaz G. E., Armagan B., AFŞAR B., DEMİRCİ U., Gulbahar O., Gumusay O., BİLGETEKİN I., Ozet A., Uner A. CHEMOTHERAPY, vol.63, no.1, pp.39-45, 2018 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **Anxiety and Depression and Quality of Life in Young Breast Cancer Patients Receiving Radiotherapy Treatment and Their Caregivers**
KARACA F., AKBULUT S., MENTEŞ S., SERTDEMİR Y., BAŞBAYRAKTAR B., ÇETİN B.
International Journal of Medical Science and Innovative Research (IJMSIR), vol.3, no.5, pp.105-117, 2018
(Refereed Journals of Other Institutions)
- II. **Managing Synchronous Liver Metastases in Colorectal Cancer.**
ÇETİN B., BİLGETEKİN İ., CENGİZ M., ÖZET A.
Indian J Surg Oncol, 2018 (Refereed Journals of Other Institutions)
- III. **Hepatotoxicity of vascular endothelial growth factor receptortyrosine kinase inhibitors: clinical practice and evidence**
ÇETİN B., Bilgetekin I., CENGİZ M., ÖZET A.
Drugs Therapy Perspectives, 2017 (Refereed Journals of Other Institutions)
- IV. **Mide Adenokarsinom: Genomik ve Hedefe Yönelik Tedavi Üzerine Bir Güncelleme**
ÇETİN B., ÖZET A.
Türkiye Klinikleri, 2017 (Other Refereed National Journals)
- V. **Antiangiogenic therapy in ovarian cancer – for whom and when?**
Bilgetekin I., ÇETİN B., ÖZET A.
Current Gynecologic Oncology, 2017 (Refereed Journals of Other Institutions)
- VI. **Advances of Molecular Targeted Therapy in Gastric Cancer**
ÇETİN B., GÜMÜŞAY Ö., CENGİZ M., ÖZET A.
J Gastrointest Cancer, 2016 (Refereed Journals of Other Institutions)

Refereed Congress / Symposium Publications in Proceedings

- I. **TÜRKİYE'DE METASTATİK MEME KANSERİNDE HER2 HEDEFLİTEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLİLİKVERİLERİ**
ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B. , SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., OLGUN P., ŞAKALAR T., AKTAŞ B. Y. , DEĞİRMENCİOĞLU S., et al.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 24 March 2018

Supported Projects

ÇETİN B., OLGUN N. V. , Project Supported by Higher Education Institutions, CERB B2 HER2 Pozitif Transtuzumab Tabanlı Tedavi Alan Meme Kanseri Hastalarında WBP2 Ekspresyonunun Prognostik Önemi, 2020 - 2021

Citations

Total Citations (WOS):1

h-index (WOS):1